RxDoctor Payments Data

Kimberly Evans

Family · Columbus, GANPI 1902656044

Payments from drug & device makers

$2,194in general payments, 2019–2025

Across 73 payments — averaging $30.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$436
  • Lilly USA, LLC$364
  • BETA Bionics, Inc.$189
  • Bayer$188
  • AstraZeneca$168
  • Mannkind Corporation$148
  • plus $702 from 15 others

What the payments were for

  • Food & beverage$2,15298%
  • Education$432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,194 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$5,732
Medicare patients
73
Services billed
2,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$75,156
MounjaroTirzepatide33$51,081
FarxigaDapagliflozin Propanediol21$28,847
JardianceEmpagliflozin12$15,447
KerendiaFinerenone11$11,998
VascepaIcosapent Ethyl15$7,918
Tresiba Flextouch U-100Insulin Degludec12$7,903
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,169
SynthroidLevothyroxine Sodium19$1,659
Levothyroxine Sodium69$807
Metformin Hcl ErMetformin Hcl21$240
Glimepiride11$219
Metformin Hcl15$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$75,15653 claims
Lilly USA, LLCMounjaro$364$51,08133 claims
AstraZenecaFarxiga$168$28,84721 claims
BayerKerendia$188$11,99811 claims
AbbVieSynthroid$26$1,65919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →